# Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

> **NCT02399410** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 60 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** perioperative chemotherapy plus bevacizumab
- **PROCEDURE:** cytoreductive surgery
- **DRUG:** Intraperitoneal Oxaliplatin

## Key facts

- **NCT ID:** NCT02399410
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-04
- **Primary completion:** 2023-11-09
- **Final completion:** 2023-11-09
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2024-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02399410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02399410, "Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02399410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*